CHQSXP(SZ:000565)2023-10-26 16:00Financial Performance - The company's revenue for Q3 2023 was ¥120,519,391.14, an increase of 2.70% compared to the same period last year[4]. - Total operating revenue for Q3 2023 reached ¥376,956,324.81, an increase of 7.1% compared to ¥350,809,415.64 in Q3 2022[25]. - The net profit for Q3 2023 was -16,121,648.58 CNY, compared to a net profit of 86,228,077.40 CNY in the same period last year, indicating a significant decline[26]. - The net profit attributable to shareholders decreased by 47.59% to ¥2,728,248.20, while the net profit after deducting non-recurring gains and losses dropped by 39.76% to ¥2,608,834.27[4]. - The company reported a total comprehensive income of -14,935,908.88 CNY for Q3 2023, compared to 84,453,613.79 CNY in the same quarter last year[26]. - The company's net profit margin has been negatively impacted, with a significant drop in profitability metrics compared to the previous year[25]. Cash Flow and Liquidity - The cash flow from operating activities showed a net outflow of ¥17,036,259.37, a decline of 206.59% compared to the same period last year[9]. - The net cash flow from operating activities decreased by 206.59% compared to the same period last year, primarily due to an increase in cash paid for purchasing goods[13]. - Cash and cash equivalents decreased to ¥311,478,791.48 as of September 30, 2023, down from ¥331,305,633.56 at the beginning of the year[22]. - The net increase in cash and cash equivalents was -¥13,671,695.58, a decrease of 148.85% compared to the previous year[9]. - Cash and cash equivalents at the end of Q3 2023 were 307,207,334.98 CNY, down from 327,554,185.76 CNY at the end of Q3 2022, a decrease of about 6.8%[28]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,579,803,278.12, a decrease of 1.89% from the end of the previous year[4]. - Total assets as of September 30, 2023, amounted to ¥1,579,803,278.12, a decrease from ¥1,610,216,265.98 at the start of the year[23]. - Total liabilities decreased to ¥302,075,112.00 from ¥311,048,307.68, reflecting a reduction of 2.3%[23]. - Non-current assets totaled ¥1,011,013,094.69, down from ¥1,060,141,241.91, indicating a decline of 4.6%[22]. Investment and Shareholder Information - The company's investment income plummeted by 123.81% to -¥22,490,075.58 due to losses from a joint venture[9]. - The largest shareholder, Chongqing Life Science Technology and New Materials Industry Group Co., Ltd., holds 40.55% of the shares, amounting to 175,808,982 shares, with 87,904,491 shares pledged[16]. - As of September 30, 2023, the company holds 40,464,500 shares of Beijing Beilu Pharmaceutical Co., Ltd., representing an 8.23% ownership stake[20]. - The company holds a 33% stake in Xinjiang Xinhui Gorge Clean Energy Co., Ltd., which has been providing financial support and guarantees[19]. Operating Costs and Expenses - Total operating costs for Q3 2023 were ¥368,946,619.53, up from ¥358,995,290.98 in the same period last year, reflecting a growth of 2.6%[25]. - The company incurred operating expenses of 230,568,679.58 CNY in Q3 2023, compared to 179,462,739.28 CNY in the same period last year, representing an increase of approximately 28.5%[27]. Borrowings and Financing Activities - The company raised 65,000,000.00 CNY through borrowings in Q3 2023, compared to 50,000,000.00 CNY in the previous year, marking a 30% increase[28]. - The net cash flow from financing activities increased by 56.69% compared to the same period last year, primarily due to a reduction in bank loan scale in the previous year[13]. Accounts Receivable and Impairment - The accounts receivable increased by 76.68% to ¥130,616,709.49, primarily due to payment settlements based on project progress[10]. - The company reported a significant increase in credit impairment losses by 705.80% to -¥1,494,498.11, due to the absence of prior year recoveries[12].